October 6, 2025

Antigen & Antibody Rapid Test Kits” are lateral flow immunoassays (LFIAs) designed to detect either pathogen antigens (e.g., nucleocapsid proteins) or host antibodies (IgM/IgG/total Ig) in minutes. This guide focuses on research, surveillance, and method-comparison contexts and avoids clinical claims. Background primers on serologic and antigen testing are available from CDC (serologic testing overview) and

Scope and context “Brucella antibody rapid tests” are lateral flow immunoassays (LFIA) intended to detect host antibodies to Brucella spp. in serum, plasma, or whole blood within ~10–20 minutes. They complement established agglutination/ELISA methods used by public health and veterinary networks (e.g., RBT, BAPA, SAT/BMAT, CF, FPA, ELISA). For background on brucellosis epidemiology, diagnostics, and

Introduction: Why an “LNP Kit for Fast General In Vitro Delivery”? Lipid nanoparticles (LNPs) have become a standard non-viral delivery platform for nucleic acids (mRNA, siRNA, plasmid DNA) due to their capacity to protect cargo, mediate cellular uptake, and facilitate endosomal escape. PMC+2PMC+2 Commercial “LNP kits” simplify formulation by providing pre-optimized lipid mixtures, buffers, and

Concept overview: why “Ultra-Universal” TOPO? Topoisomerase-mediated cloning (commonly known as TOPO™ cloning) couples vector linearization with covalently pre-loaded vaccinia DNA topoisomerase I to capture PCR amplicons rapidly—without ligase or restriction digestion. Mechanistically, Topo I forms a transient 3′-phosphotyrosyl bond at specific vector sites; upon insert annealing (TA) or alignment (blunt), the enzyme resolves the intermediate,